Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 2867 • 2017 ACR/ARHP Annual Meeting
CD39 Positive Regulatory T Cells As a Biomarker of Responsiveness to Methotrexate in Rheumatoid Arthritis
Vikas Gupta¹, Shobhita Katiyar², Ankita Singh², Ramnath Misra¹ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: About 30-40% of patients with RA do not respond to MTX, the first-line therapy in RA. Early identification of responders may allow the use…
Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting
Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate
Michael D. George¹, Brian Sauer², Chia-Chen Teng, MS², Grant Cannon², Bryant R. England³, Gail S. Kerr⁴, Ted R. Mikuls⁵ and Joshua Baker⁶, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴VAMC, Georgetown University, Washington, DC, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…
Abstract Number: 443 • 2017 ACR/ARHP Annual Meeting
Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institute de Rheumatologie, Montreal, QC, Canada, ¹⁰Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is recommended as part of initial therapy in early RA, but practices range widely. The objective of this analysis was to describe…
Abstract Number: 461 • 2017 ACR/ARHP Annual Meeting
Additions to Methotrexate with Conventional and Biologic Dmards in Rheumatoid Arthritis: Are There Differences in Subsequent Time to Treatment Failure?
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University, Montreal, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁰University of Toronto, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Our objective was to compare RA treatment strategies with conventional and biologic DMARDs after an initial MTX strategy was ineffective or associated with a…
Abstract Number: 1587 • 2016 ACR/ARHP Annual Meeting
A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo As Co-Therapy with Methotrexate in Active Rheumatoid Arthritis (RA)
Alan J Kivitz¹, Ramesh Gupta², Guillermo Valenzuela³, Edwin Smith⁴, Quaiser Rehman⁵, Hisham El Kadi⁶, Elizabeth Bretton⁷, Jacob A. Aelion⁸, Anurekh Chadha⁹, John Tesser¹⁰, Douglas Hough¹¹, Shimon Korish¹², Peter H. Schafer¹³, Garth Ringheim¹⁴, Donna Sutherland¹⁵ and Li LI¹⁶, ¹Altoona Arthritis & Osteo Ctr, Duncansville, PA, ²Private Practice, Memphis, TN, ³Integral Rheumatology & Immunology Specialists, Fort Lauderdale, FL, ⁴Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Rheumatology Clinic of Houston, Houston, TX, ⁶Arthritis & Osteoporosis Associates, Freehold, NJ, ⁷Albuquerque Clinical Trials, Albuquerque, NM, ⁸West Tennessee Research Institute, Jackson, TN, ⁹Department of Rheumatology, Austin Regional Clinic, Austin, TX, ¹⁰Arizona Arthritis and Rheumatology Research, PLLC, Pheonix, AZ, ¹¹Clinical Research, Celgene Corporation, Warren, NJ, ¹²33 Technology Drive, Celgene Corporation, Warren, NJ, ¹³Department of Translational Development, Celgene Corporation, Summit, NJ, ¹⁴Translational Medicine, Celgene Corporation, Summit, NJ, ¹⁵Clinical Research, Celgene Corporation, Summit, NJ, ¹⁶Biostatistics, Celgene Corporation, Summit, NJ
Methods: 47 adult female RA subjects were randomized 1:1 CC-292 375 mg PO daily or placebo (PBO). Subjects were required to have a diagnosis of…
Abstract Number: 1606 • 2016 ACR/ARHP Annual Meeting
Metrotexate Treatment Inmunomodulate the Abnormal Cytokine Expression Present in NaïVe Rheumatoid Arthritis Patients
Jorge Monserrat Sanz¹, Ana Maria Gómez Lahoz¹, Maria Dolores Sosa Reina¹, Cristina Bohórquez Heras², Atusa Movasat², Ana Pérez Gómez², Lucía Ruiz Gutiérrez², Ana Sánchez Atrio², Eduardo Cuende Quintana², M José León², David Diaz³, Fernando Albarrán Hernández² and Melchor Alvarez-Mon^2,3, ¹Medicine and Medical Specialities, Laboratory of Immune System Diseases, Department of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain, ²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ³Laboratory of Immune System Diseases, Department of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain
Background/Purpose: Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA) patients. Since the first reports of the efficacy of low-dose MTX in…
Abstract Number: 1638 • 2016 ACR/ARHP Annual Meeting
Antibody Mediated Immunity Drives Response to Methotrexate Treatment in Rheumatoid Arthritis Patients
Boel Brynedal¹, Helga Westerlind², Lasse Folkersen^3,4, Leonid Padyukov⁵, Nancy Vivar⁵, Anca I Catrina⁶, Lars Klareskog⁵ and Louise Berg⁵, ¹Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska, Sweden, ²Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark, ⁵Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden, ⁶Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Methotrexate (MTX) is the first line treatment for Rheumatoid Arthritis (RA) in Sweden, but one third of patients do not experience satisfying treatment response.…
Abstract Number: 2449 • 2016 ACR/ARHP Annual Meeting
Infertility in Women with Rheumatoid Arthritis
Megan E. B. Clowse, Gary McDaniel and Amanda M. Eudy, Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Rheumatoid arthritis (RA) is a rheumatic disease that can affect women of reproductive age, and data suggest infertility is increased in RA. The objective…
Abstract Number: 2477 • 2016 ACR/ARHP Annual Meeting
Short Term Clinical Response to Initial Treatment with High Versus Low Dose Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients
SA Bergstra¹, CF Allaart¹, R van den Berg¹, A Chopra², N Govind³, MJ Santos⁴, TWJ Huizinga⁵ and RBM Landewé^6,7, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Center for Rheumatic Diseases, Pune, India, Pune, India, ³Department of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, Johannesburg, South Africa, ⁴Rheumatology, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ⁵Leiden University Medical Centre, Leiden, Netherlands, ⁶Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands, ⁷Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of methotrexate (MTX) for newly diagnosed rheumatoid…
Abstract Number: 2482 • 2016 ACR/ARHP Annual Meeting
Long Term Drug Survival of Adalimumab and Etanercept Treatment for Rheumatoid Arthritis with and without Methotrexate
I.M Visman¹, MJ l'Ami², Gertjan Wolbink³ and Mike T. Nurmohamed^4,5, ¹Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ⁴Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are effective, safe and widely used treatment for rheumatoid arthritis (RA). The therapy is often started in combination…
Abstract Number: 2507 • 2016 ACR/ARHP Annual Meeting
Assessment of Liver Fibrosis Using Transient Elastography in Patients with Rheumatoid Arthritis Exposed to Long Term Methotrexate
Min Kyung Chung¹, Seo Hwa Kim², Haneul Kim¹, Jung Hee Koh¹, Jennifer Lee³, Seung-Ki Kwok⁴, Ji Hyeon Ju⁵ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ⁴[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Methotrexate (MTX) has been recommended for the first line therapy of rheumatoid arthritis (RA), either alone or in combination with other DMARDs such as…
Abstract Number: 2510 • 2016 ACR/ARHP Annual Meeting
Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases
Jesús Tornero Molina¹, Jaime Calvo², Francisco Javier Ballina-García³, María Ángeles Belmonte⁴, Francisco J. Blanco^5,6, Miguel Angel Caracuel-Ruiz⁷, Jordi Carbonell⁸, Hector Corominas⁹, Eugenio Chamizo Carmona¹⁰, C. Hidalgo-Calleja¹¹, Jose Andres Roman Ivorra¹², José Luis Marenco de la Fuente¹³, J.V. Moreno¹⁴, Santiago Muñoz Fernandez¹⁵, Joan Miquel Nolla¹⁶, Trinidad Perez Sandoval¹⁷, Raimon Sanmarti¹⁸, Pilar Trenor¹⁹, Claudia Urrego²⁰, Javier Vidal¹ and José Rosas²¹, ¹Rheumatology Unit, Hospital de Guadalajara, Guadalajara, Spain, ²Rheumatology Unit, Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ³Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ⁴Rheumatology service, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁵Osteoarticular and Aging Research Lab, INIBIC Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain, ⁷Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁸Rheumatology Unit, Hospital del Mar, Barcelona, Spain, ⁹Rheumatology, Hospital Moises Broggi, Barcelona, Spain, ¹⁰Rheumatology, Hospital de Mérida, Mérida, Spain, ¹¹University of Salamanca Hospital, Salamanca, Spain, ¹²Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ¹³Rheumatology, Hospital de Valme, Seville, Spain, ¹⁴Rheumatologist. Vall D’Hebron Hospital, Barcelona, Spain, ¹⁵Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ¹⁶Rheumatology, Bellvitge University Hospital, Barcelona, Spain, ¹⁷Rheumatology, Hospital de León, LEÓN, Spain, ¹⁸Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁹Rheumatology Unit, Hospital Clínico de Valencia, Valencia, Spain, ²⁰Hospital G. Segovia, Segovia, Spain, ²¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain
Background/Purpose: To develop recommendations for the management of parenteral MTX in rheumatic diseases based on best evidence and experience. Methods: A group of 21 experts…
Abstract Number: 2516 • 2016 ACR/ARHP Annual Meeting
Concomitant Use of Oral Vs. Subcutaneous Methotrexate at Biologic Initiation: A Comparison of Biologic Treatment Survival in a Rheumatoid Arthritis Cohort
Carter Thorne¹, Mohammad Movahedi², Angela Cesta², Xiuying Li², Emmanouil Rampakakis³, John S. Sampalis⁴ and Claire Bombardier⁵, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Previous studies have shown differences in the effectiveness and survival of subcutaneous vs. oral methotrexate. Furthermore, concurrent methotrexate therapy has been shown to enhance…
Abstract Number: 2569 • 2016 ACR/ARHP Annual Meeting
Restoration of Decreased Lymphocyte Counts and the Shift to Th1 and Effector Memory CD8+T Cell Subsets Associate with Spontaneous Regression of Lympho-Proliferative Disorders Developed in RA Patients Treated with Methotrexate
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹, Koichi Amano², Michihide Tokuhira³ and Tsutomu Takeuchi¹, ¹Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ³Department of Hematology, Saitama Medical Center, Saitama Medical University., Saitama, Japan
Background/Purpose: Methods: Forty-three RA patients complicated with LPD were identified and 76 control patients were selected. Among the 43 LPD patients, 28 were regressive and…
Abstract Number: 3091 • 2016 ACR/ARHP Annual Meeting
Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate
Cem Gabay¹, Jérôme Msihid², Nikki Daskalakis³, Neil Graham⁴, Anne Barbot⁵, Moshe Zilberstein³ and Anita Boyapati⁴, ¹University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland, ²Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, NJ, France, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, France
Background/Purpose: Patients with RA develop bone and joint damage due to chronic inflammation that is mediated by a destructive synovial pannus.1 The pannus is composed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].